By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Nautilus Neurosciences, Inc. 

135 Rte. 202/206

Bedminster  New Jersey  07921  U.S.A.
Phone: 908-203-4600 Fax: n/a


SEARCH JOBS


Industry
Pharmaceutical






Company News
Depomed, Inc. (DEPO) BagsCAMBIA® Migraine Med From Nautilus Neurosciences, Inc. For $48.7 Million 12/18/2013 6:58:02 AM
Nautilus Neurosciences, Inc. Announces Co-Promotion Agreement for Lorzone™ 6/12/2013 10:28:59 AM
Eric Liebler, Founder and Former President of Nautilus Neurosciences, Inc., Joins ElectroCore 1/9/2013 7:33:13 AM
Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA(R) for the Acute Treatment of Migraine 3/20/2012 8:53:37 AM
Nautilus Neurosciences, Inc. Announces New Patent Issued 2/1/2012 9:52:06 AM
Nautilus Neurosciences, Inc. Appoints Peter Lankau as Executive Chairman 11/8/2011 8:51:01 AM
Nautilus Neurosciences, Inc. Selects Mission3 OnDemand Virtual Data Room 8/19/2011 9:18:42 AM
Nautilus Neurosciences, Inc. and Tribute Pharmaceuticals Announce Exclusive Canadian License for CAMBIA(TM) (diclofenac potassium for oral solution) for the Acute Treatment of Migraine 11/16/2010 6:43:12 AM
Nautilus Neurosciences, Inc.: New Analysis of CAMBIA(TM) Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology 10/26/2010 7:13:24 AM
Nautilus Neurosciences, Inc. and Mission Pharmacal Company Announce Exclusive Co-Promotion Agreement for CAMBIA(TM) (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market 10/6/2010 6:53:35 AM
12
//-->